Is INGN a good stock to buy right now?

Based on our 6-factor quantitative model, Inogen Inc (INGN) receives a "Reduce" rating with a composite score of 37.1/100. It is ranked #2,014 out of 4,446 stocks. Key factor scores: Quality 37/100, Value 22/100, Momentum 31/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for INGN?

Inogen Inc (INGN) has a "Reduce" rating and 2-star score. The composite score of 37.1 ranks it #2,014 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is INGN in?

Inogen Inc operates in the Healthcare sector (Medical Equipment industry) with a market cap of $171 million. It is classified as a micro-cap stock.

Does INGN pay a dividend?

INGN does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is INGN's P/E ratio?

P/E ratio data is not currently available for INGN, which may indicate the company is not yet profitable.

How profitable is INGN?

INGN's quality factor score is 37/100. Gross margin: 45.1%. ROE: -11.2% vs sector average -43.5%. Margins are moderate to low, reflecting competitive market dynamics.

How is INGN valued compared to peers?

INGN's value factor score is 22/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is INGN's debt level?

INGN's debt-to-equity ratio is 55%. Sector average: 32%. Moderate leverage is normal for established companies.

INGN has a beta of 0.81, meaning it tracks the market. Stability score: 56/100.

Does INGN have high short interest?

INGN's short interest factor score is 64/100 (higher = less short selling). Moderate short interest.

INGN Stock Analysis: Top Micro-Cap Reduce (Score 37.1/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
INGN	-4.95%	+1.93%	+1.77%	-5.80%	-10.59%	-	-	-
Industry Proxy XLV	-1.35%	+0.34%	-3.81%	-4.84%	+9.21%	-	-	-
U.S. Market SPY	-0.07%	+3.60%	+0.34%	-0.36%	+29.52%	-	-	-
Alpha vs Market	-4.89%	-1.67%	+1.43%	-5.44%	-40.12%	-	-	-
Alpha vs Sector	-3.60%	+1.59%	+5.58%	-0.97%	-19.80%	-	-	-

Metric	INGN	Benchmark
P/E Ratio	-8.5x	-136%
EV/EBITDA	—	—
Price / Book	1.0x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
INGN Inogen Inc	37	37	22	31	-	-11.2%	45.1%	-6.1%	4.1%	55.0x	$171M

Key Ratio	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Gross Margin %	0.5%	0.4%	0.5%	0.4%	0.4%	0.5%	0.4%	0.2%	0.7%	0.5%	0.5%
Operating Margin %	-0.1%	-0.1%	-0.1%	-0.3%	-0.2%	0.0%	-0.0%	0.0%	0.1%	0.1%	0.1%
EBITDA Margin %	-0.0%	-0.0%	-0.1%	-0.3%	-0.2%	0.1%	0.0%	0.1%	0.1%	0.2%	0.2%
Net Margin %	-0.1%	-0.1%	-0.1%	-0.3%	-0.2%	-0.0%	-0.0%	0.0%	0.1%	0.1%	0.1%
FCF Margin %	-4.6%	-	0.8%	-	-	-	10.6%	7.0%	9.7%	23.1%	14.5%
ROE %	-0.1%	-0.1%	-0.2%	-0.5%	-0.3%	-0.0%	-0.0%	0.1%	0.2%	0.1%	0.1%
ROA %	-0.1%	-0.1%	-0.1%	-0.3%	-0.2%	-0.0%	-0.0%	0.0%	0.1%	0.1%	0.1%
ROIC %	-26.4%	-12.4%	-55.9%	-42.2%	-22.6%	2.0%	-6.9%	10.7%	26.3%	25.9%	20.2%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

Gross Margin %

0.5%

0.4%

0.5%

0.4%

0.5%

0.4%

0.2%

0.7%

0.5%

Operating Margin %

-0.1%

-0.3%

-0.2%

0.0%

-0.0%

0.0%

0.1%

EBITDA Margin %

-0.0%

-0.1%

-0.3%

-0.2%

0.1%

0.0%

0.1%

0.2%

Net Margin %

-0.1%

-0.3%

-0.2%

-0.0%

0.0%

0.1%

FCF Margin %

-4.6%

0.8%

10.6%

7.0%

9.7%

23.1%

14.5%

ROE %

-0.1%

-0.2%

-0.5%

-0.3%

-0.0%

0.1%

0.2%

0.1%

ROA %

-0.1%

-0.3%

-0.2%

-0.0%

0.0%

0.1%

ROIC %

-26.4%

-12.4%

-55.9%

-42.2%

-22.6%

2.0%

-6.9%

10.7%

26.3%

25.9%

20.2%

Line Item	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
	$356M	$349M	$336M	$316M	$377M	$358M	$308M	$534M	$537M	$249M	$203M	$159M
	—	$194M	—	$189M	$224M	$182M	—	—	—	—	—	—
	$160M	$154M	$155M	$127M	$154M	$176M	$138M	$344M	$357M	$121M	$97M	$76M
Gross Margin	45.1%	44.2%	46.1%	40.1%	40.7%	49.3%	44.8%	23.7%	66.5%	48.6%	48.0%	48.0%
	—	$19M	$22M	$21M	$22M	$17M	$14M	$9M	$7M	$5M	$5M	$4M
Depreciation	—	$16M	$21M	$17M	$15M	$13M	$19M	$14M	$11M	$12M	$14M	$14M
Total Operating Expenses	—	$184M	—	$236M	$239M	$167M	—	—	—	—	—	—
	-$29M	-$30M	-$43M	-$109M	-$85M	$9M	-$12M	$20M	$38M	$28M	$23M	$15M
EBIT	-$29M	-$30M	-$43M	-$109M	-$85M	$9M	-$12M	$20M	$38M	$28M	$23M	$15M
EBITDA	-$12M	-$14M	-$21M	-$92M	-$70M	$22M	$12M	$38M	$48M	$41M	$36M	$29M
Operating Margin	-8.1%	-8.7%	-12.7%	-34.6%	-22.6%	2.6%	-3.9%	2.7%	7.1%	11.1%	11.3%	9.5%
EBITDA Margin	-3.5%	-4.1%	-6.2%	-29.3%	-18.6%	6.2%	4.0%	7.1%	9.0%	16.5%	17.8%	18.0%
	—	—	—	—	—	—	—	—	—	—	$6K	$22K
	—	-$23M	—	-$102M	-$83M	$9M	—	—	—	—	—	—
Income Tax Expense	—	-$632K	-$588K	$105K	$504K	$15M	$549K	$3M	-$11M	$9M	$2M	$3M
	-$22M	-$23M	-$36M	-$102M	-$84M	-$6M	-$6M	$21M	$52M	$21M	$21M	$12M
Net Margin	-6.1%	-6.5%	-10.7%	-32.5%	-22.2%	-1.8%	-1.9%	2.9%	9.7%	8.4%	10.1%	7.3%
	$-0.86	$-0.86	$-1.52	$-4.42	$-3.67	$-0.28	$-0.27	$0.96	$2.44	$1.02	$1.02	$0.60
Diluted EPS	$-0.86	$-0.86	$-1.52	$-4.42	$-3.67	$-0.28	$-0.27	$0.96	$2.44	$1.02	$1.02	$0.60
Weighted Avg Basic	—	27M	—	23M	23M	22M	—	—	—	—	—	—
Weighted Avg Diluted	—	27M	—	23M	23M	22M	—	—	—	—	—	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

$356M

$349M

$336M

$316M

$377M

$358M

$308M

$534M

$537M

$249M

$203M

$159M

—

$194M

—

$189M

$224M

$182M

—

$160M

$154M

$155M

$127M

$154M

$176M

$138M

$344M

$357M

$121M

$97M

$76M

Gross Margin

45.1%

44.2%

46.1%

40.1%

40.7%

49.3%

44.8%

23.7%

66.5%

48.6%

48.0%

—

$19M

$22M

$21M

$22M

$17M

$14M

$9M

$7M

$5M

$4M

Depreciation

—

$16M

$21M

$17M

$15M

$13M

$19M

$14M

$11M

$12M

$14M

Total Operating Expenses

—

$184M

—

$236M

$239M

$167M

—

-$29M

-$30M

-$43M

-$109M

-$85M

$9M

-$12M

$20M

$38M

$28M

$23M

$15M

EBIT

-$29M

-$30M

-$43M

-$109M

-$85M

$9M

-$12M

$20M

$38M

$28M

$23M

$15M

EBITDA

-$12M

-$14M

-$21M

-$92M

-$70M

$22M

$12M

$38M

$48M

$41M

$36M

$29M

Operating Margin

-8.1%

-8.7%

-12.7%

-34.6%

-22.6%

2.6%

-3.9%

2.7%

7.1%

11.1%

11.3%

9.5%

EBITDA Margin

-3.5%

-4.1%

-6.2%

-29.3%

-18.6%

6.2%

4.0%

7.1%

9.0%

16.5%

17.8%

18.0%

—

$6K

$22K

—

-$23M

—

-$102M

-$83M

$9M

—

Income Tax Expense

—

-$632K

-$588K

$105K

$504K

$15M

$549K

$3M

-$11M

$9M

$2M

$3M

-$22M

-$23M

-$36M

-$102M

-$84M

-$6M

$21M

$52M

$21M

$12M

Net Margin

-6.1%

-6.5%

-10.7%

-32.5%

-22.2%

-1.8%

-1.9%

2.9%

9.7%

8.4%

10.1%

7.3%

$-0.86

$-1.52

$-4.42

$-3.67

$-0.28

$-0.27

$0.96

$2.44

$1.02

$0.60

Diluted EPS

$-0.86

$-1.52

$-4.42

$-3.67

$-0.28

$-0.27

$0.96

$2.44

$1.02

$0.60

Weighted Avg Basic

—

27M

—

23M

22M

—

Weighted Avg Diluted

—

27M

—

23M

22M

—

Inogen Inc (INGN) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does Inogen Inc Do?

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California. Inogen Inc (INGN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Nabil Shabshab and employs approximately 1,030 people, headquartered in Goleta, California. With a market capitalization of $171M, INGN is one of the notable companies in the Healthcare sector.

Inogen Inc (INGN) Stock Rating — Reduce (April 2026)

As of April 2026, Inogen Inc receives a Reduce rating with a composite score of 37.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.INGN ranks #2,014 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Inogen Inc ranks #218 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

INGN Stock Price and 52-Week Range

Inogen Inc (INGN) currently trades at $6.33. The stock lost $0.33 (5.0%) in the most recent trading session. The 52-week high for INGN is $9.13, which means the stock is currently trading -30.7% from its annual peak. The 52-week low is $5.34, putting the stock 18.5% above its annual trough. Recent trading volume was 314K shares, suggesting relatively thin trading activity.

Is INGN Overvalued or Undervalued? — Valuation Analysis

Inogen Inc (INGN) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.96x, versus the sector average of 2.75x. The price-to-sales ratio is 0.52x, compared to 1.66x for the average Healthcare stock.

At current multiples, Inogen Inc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Inogen Inc Profitability — ROE, Margins, and Quality Score

Inogen Inc (INGN) earns a quality factor score of 37/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -11.2%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -7.2% versus the sector average of -33.1%.

On a margin basis, Inogen Inc reports gross margins of 45.1%, compared to 71.5% for the sector. The operating margin is -8.1% (sector: -66.1%). Net profit margin stands at -6.1%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 4.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

INGN Debt, Balance Sheet, and Financial Health

Inogen Inc has a debt-to-equity ratio of 55.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.12x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $106M.

INGN has a beta of 0.81, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Inogen Inc is 56/100, reflecting average volatility within the normal range for its sector.

Inogen Inc Revenue and Earnings History — Quarterly Trend

In TTM 2026, Inogen Inc reported revenue of $356M and earnings per share (EPS) of $-0.86. Net income for the quarter was $-22M. Gross margin was 45.1%. Operating income came in at $-29M.

In FY 2025, Inogen Inc reported revenue of $349M and earnings per share (EPS) of $-0.86. Net income for the quarter was $-23M. Gross margin was 44.2%. Revenue grew 3.9% year-over-year compared to FY 2024. Operating income came in at $-30M.

In Q3 2025, Inogen Inc reported revenue of $92M and earnings per share (EPS) of $-0.20. Net income for the quarter was $-5M. Gross margin was 44.7%. Revenue grew 4.0% year-over-year compared to Q3 2024. Operating income came in at $-7M.

In Q2 2025, Inogen Inc reported revenue of $92M and earnings per share (EPS) of $-0.15. Net income for the quarter was $-4M. Gross margin was 44.8%. Revenue grew 4.0% year-over-year compared to Q2 2024. Operating income came in at $-6M.

Over the past 8 quarters, Inogen Inc has demonstrated a growth trajectory, with revenue expanding from $89M to $356M. Investors analyzing INGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

INGN Dividend Yield and Income Analysis

Inogen Inc (INGN) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

INGN Momentum and Technical Analysis Profile

Inogen Inc (INGN) has a momentum factor score of 31/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 32/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.

INGN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Inogen Inc (INGN) ranks #218 out of 838 stocks based on the Blank Capital composite score. This places INGN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing INGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full INGN vs S&P 500 (SPY) comparison to assess how Inogen Inc stacks up against the broader market across all factor dimensions.

INGN Next Earnings Date

No upcoming earnings date has been announced for Inogen Inc (INGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy INGN? — Investment Thesis Summary

The quantitative profile for Inogen Inc suggests caution. The quality score of 37/100 flags below-average profitability. The value score of 22/100 indicates premium valuation. Momentum is weak at 31/100, a headwind for near-term performance.

In summary, Inogen Inc (INGN) earns a Reduce rating with a composite score of 37.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on INGN stock.

Related Resources for INGN Investors

Explore more research and tools: INGN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare INGN head-to-head with peers: INGN vs AZN, INGN vs SLGL, INGN vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inogen appoints new CFO (NASDAQ:INGN)

Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?

Inogen (INGN) Surges 6.9%: Is This an Indication of Further Gains?

Global Anesthesia and Respiratory Devices Market Size/Share Worth USD 100.5 Billion by 2035 at a 5.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

Inogen Inc (INGN) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does Inogen Inc Do?

Inogen Inc (INGN) Stock Rating — Reduce (April 2026)

INGN Stock Price and 52-Week Range

Is INGN Overvalued or Undervalued? — Valuation Analysis

Inogen Inc Profitability — ROE, Margins, and Quality Score

INGN Debt, Balance Sheet, and Financial Health

Inogen Inc Revenue and Earnings History — Quarterly Trend

INGN Dividend Yield and Income Analysis

INGN Momentum and Technical Analysis Profile

INGN vs Competitors — Healthcare Sector Ranking and Peer Comparison

INGN Next Earnings Date

Should You Buy INGN? — Investment Thesis Summary

Related Resources for INGN Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

Inogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Inogen appoints new CFO (NASDAQ:INGN)

Veracyte (VCYT) Down 15.4% Since Last Earnings Report: Can It Rebound?

Inogen (INGN) Surges 6.9%: Is This an Indication of Further Gains?

Global Anesthesia and Respiratory Devices Market Size/Share Worth USD 100.5 Billion by 2035 at a 5.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)